Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenues of $74.7 million, a 40% decline year-over-year, primarily due to the winding down of the seed business and reduced demand for crop inputs in Argentina [6][8][9] - For the full fiscal year, revenues totaled $335.3 million, down 28% year-over-year, with declines across all segments [8][12] - Adjusted EBITDA for Q4 was -$4.5 million, down from $19.9 million the previous year, largely due to a $22.7 million reduction in gross profit [13][15] - Full-year EBITDA was $28.3 million, down from $81.4 million in FY24, reflecting a $54.6 million decline in gross profit [15][18] Business Line Data and Key Metrics Changes - In the seed segment, revenues were $63.9 million for the year, a reduction of 34%, attributed to the transition to a royalty-based model [9][12] - Crop protection revenues for the full year were $181.9 million, down 20%, with a strong decline in Argentina offsetting growth in bioprotection in the U.S. and adjuvants in Brazil [8][12] - Crop nutrition revenues were $89.5 million, down 37% year-over-year, driven by lower microbiota fertilizer sales in Argentina [8][12] Market Data and Key Metrics Changes - International sales of core technologies grew, with adjuvant sales in Brazil almost doubling and bioprotection products in the U.S. growing nearly 40% [7] - The company experienced a significant decline in sales in Argentina due to adverse on-farm economics and reduced spending on agricultural inputs [5][6] Company Strategy and Development Direction - The company is focusing on cash generation and improving working capital management, targeting a running rate of five to six months of sales [19][20] - Cost structure adjustments are being accelerated, with targeted operating expense savings of around 10%-12% [19][20] - The company aims to scale up biological initiatives and support key partners in Latin America while onboarding new partnerships in the U.S. and Australia [21][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in fiscal 2025, primarily due to macroeconomic shifts in Argentina and a lack of inventory incentives for clients [4][5] - The company expects to improve EBITDA margins and progress towards a more robust balance sheet with a normalized agricultural input market in Argentina and continued growth in the U.S. and Brazil [20][21] - Management emphasized the importance of cash generation and profitability expansion over top-line growth in the current environment [25][26] Other Important Information - Total financial debt stood at $255.5 million, slightly lower than the previous year, with cash and equivalents totaling $34.6 million [17][18] - The company is working closely with creditors to comply with financial obligations and manage upcoming debt maturities [20] Q&A Session Summary Question: What metrics should be focused on in the next six to nine months? - Management indicated that cash generation and profitability expansion will be key metrics, with less emphasis on top-line growth under current circumstances [25][26] Question: Can you elaborate on cost savings initiatives? - Management expects to achieve quarterly savings of $3 million-$3.5 million through workforce streamlining and right-sizing capacities [29][31] Question: What was the gross profit from the Syngenta agreement in FY2025? - The gross profit from the Syngenta agreement for FY2025 was approximately $18 million, down from $16 million in the previous year [35][37] Question: What efforts have been made regarding the HB4 product? - Management highlighted a key agreement in soybeans to reposition HB4 technology, which is expected to generate revenues in the upcoming fiscal year [43][44] Question: What is the current state of inventories in the channel? - Management noted that inventory levels in Argentina have been almost depleted, indicating a potential recovery in sales [62][63]

Core Viewpoint - The company, Andermatt A (000553.SZ), confirmed that its main business focuses on crop protection products and does not involve any antibiotic-related business [2] Company Summary - Andermatt A's primary business is in crop protection products [2] - The company does not engage in the antibiotic sector [2]

Group 1 - The global crop protection product inventory levels are showing signs of normalization after an unprecedented destocking in 2023, with manufacturers cautiously optimistic about the market in the second half of 2025 [2] - The global crop protection market is expected to decline by 6.0% year-on-year in 2024, reaching approximately $75.4 billion, due to macroeconomic factors and low agricultural prices affecting farmer incomes [2] - Crop protection companies have faced challenges over the past two years, with executives acknowledging the difficult period for the industry, but there are expectations for performance improvement in 2025 due to stabilized inventory and demand recovery [2] Group 2 - The U.S. crop protection market is projected to grow by 2.1% in 2025, reaching $77 billion, despite ongoing inflation and trade tensions impacting farmer incomes [3] - Tariff impacts on crop protection companies have been manageable, with estimates of tariff effects on Corteva's crop protection business reduced from $50 million to $25-30 million, aided by supply chain diversification [3] - U.S. farmers are proceeding with their planting plans, which is a positive sign for the crop protection market recovery [3] Group 3 - European crop protection companies face greater challenges, with Bayer anticipating increased price competition due to a surge in generic product capacity, particularly in glyphosate [4] - Bayer has announced a restructuring of its crop protection production and R&D in Germany to address the competitive pressures from Asian generic manufacturers [4]

Core Viewpoint - Company expects a significant reduction in losses for the first half of 2025 compared to the same period in 2024, with a projected net loss of between 54 million to 108 million yuan [1][2]. Financial Performance - The company anticipates a year-on-year reduction in losses primarily due to an increase in operating profit and a decrease in tax expenses, which outweighed the impact of rising financial costs [2]. - EBITDA and its profit margin are expected to grow year-on-year compared to the same period in 2024, driven by improvements in gross profit and gross margin, reflecting lower inventory costs and increased sales volume [2]. - The company projects that its sales for the first half of 2025 will remain stable compared to 2024, with a 1% increase in sales when calculated in RMB, while remaining flat in USD [2][3]. Strategic Transformation - The company is undergoing a significant transformation to address challenges in the agricultural chemical industry, including oversupply issues. The "Advancement" transformation plan, initiated in early 2024, aims to enhance profits and improve cash flow over three years [4]. - The "Advancement" plan consists of three main pillars: optimizing financial management, streamlining operational structure, and focusing on "value innovation" in niche markets [4]. - The management has indicated that the transformation plan has positively impacted key financial metrics, including EBITDA, EBITDA margin, cash flow, and overall operating expenses [4][5]. Operational Efficiency - The company is implementing cost optimization measures to lower operating costs and improve financial health, alongside transforming its operational model for greater efficiency [5]. - The company has removed several low-margin products from its portfolio to enhance profitability [6]. - Over the past year, the company's stock price has increased by nearly 70% [6].